Isotype-specific agglutination-PCR (ISAP): A sensitive and multiplex method for measuring allergen-specific IgE - 04/05/18
Doi : 10.1016/j.jaci.2017.11.021
Cheng-ting Tsai, BS a, ∗, Kaori Mukai, PhD b, ∗, Peter V. Robinson, PhD c, Melissa A. Gray, BS d, Malika B. Waschmann, BS e, Shu-Chen Lyu, BS f, g, Mindy Tsai, DMSc b, g, Rebecca S. Chinthrajah, MD f, g, Kari C. Nadeau, MD, PhD f, g, Carolyn R. Bertozzi, PhD a, h 
, Stephen J. Galli, MD b, g, i
, Stephen J. Galli, MD b, g, i a Department of Chemistry, Stanford University School of Humanities and Sciences, Stanford, Calif
b Department of Pathology, Microbiology and Immunology, Stanford University School of Medicine, Stanford, Calif
c Enable Biosciences, San Francisco, Calif
d Department of Chemical Biology, Stanford University School of Medicine, Stanford, Calif
e Department of Human Biology, Stanford University School of Humanities and Sciences, Stanford, Calif
f Division of Pulmonary and Critical Care, Department of Medicine, Stanford, Calif
g Sean N. Parker Center for Allergy and Asthma Research, Stanford, Calif
h Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, Calif
i Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, Calif
| The authors' laboratories are funded by the National Institutes of Health (grant no. R21 DK108781A, SPADA [Stanford Predictive and Diagnostics Accelerator] to C.R.B.; grant nos. U19 AI 104209 and R01 AR067145 to S.J.G.), and by the Department of Pathology, Stanford University. |
|
| Disclosure of potential conflict of interest: C.-T. Tsai is supported by a grant from the National Institutes of Health (NIH) and Stanford Predictive Diagnostics Accelerator and has a pending grant from Enable Biosciences; has patents and royalties (planned, pending, or issued) from Stanford University; and has stock/stock options from Enable Biosciences. K. Mukai is supported by a grant from Stanford University and has patents and royalties (planned, pending, or issued) from Stanford University. P. V. Robinson mentions a pending grant from Enable Biosciences; patents and potential royalties (planned, pending, or issued) from Stanford University; and stock/stock options from Enable Biosciences. M. Tsai is supported by a grant from the NIH and has patents and potential royalties (planned, pending, or issued) from Stanford University. R. S. Chinthrajah is supported by a grant from the NIH. K. C. Nadeau mentions that this work was supported by the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. C. R. Bertozzi is supported by a grant from the NIH and Stanford Predictive Diagnostics Accelerator; has a pending grant from Enable Biosciences; has patents and potential royalties (planned, pending, or issued) from Stanford University; and has stock/stock options from Enable Biosciences. S. J. Galli is supported by a grant from the NIH and has additional grants pending from the NIH; has board membership on the National Institute of Allergy and Infectious Diseases Advisory Council; and has patents (planned, pending, or issued) from Stanford University. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 5
P. 1901 - mai 2018 Retour au numéro
Article précédent
- Comparison of allergy immunotherapy medication persistence with a sublingual immunotherapy tablet versus subcutaneous immunotherapy in Germany
- Jean-Pierre Allam, Jakob N. Andreasen, Janina Mette, Niels Serup-Hansen, Eike Gunther Wüstenberg
- Epidemiologic patterns of in-hospital anaphylaxis in pediatric surgical patients
- Sara A. Sun, Xiaoyue Ma, Guohua Li, Caleb Ing
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?